Results
existing knowledge of biology, and do not represent a set of uncharacterized cellular interactions.
In order to test this assumption, we retrieved 1,129 curated cellular pathways from KEGG (1) and Pathway Interaction Database (2) as well as 40 pharmacodynamic (PD) pathways from PharmGKB (3). We found that 78% of genes in PD pathways are found also in curated pathways (p<4e -251 ). Furthermore, 60% of the gene interactions in PD pathways are found in curated pathway databases (p=0). Particularity, each of the PharmGKB PD pathways shares a significant overlap of genes with at least one curated pathway (with a median of fifteen, false discovery rate of 0.05). Of course, the number of overlapping pathways depends on the granularity by which pathways are defined, but in any case it is clear that drug-related pathways that are well-studied tend to reflect curated pathway knowledge in general.
Analysis of tiludronate constructed pathway
We analyze a small-sized drug-specific pathway for tiludronate, a non-nitrogenous bisphosphonate treating Paget's disease of the bone ( Figure S1 ). The pathway includes tiludronate drug targets, ATP6V1A and PTPN1 (red), its known pharmacogene IL1B (blue) and VCP, SQSTM1 and TNFRSF11A, associated in OMIM (4) with Paget's disease of the bone (yellow). Among the tiludronate pathway inferred genes, TRAF6 directly interacts with the three disease genes and has a known role in Osteoclastogenesis (5). The drug target PTPN1 affects TRAF6 via the Src gene, also with reported role in tiludronate mechanism of action (6, 7). PTPN1 affects the IL1B pharmacogene through STAT3 and JUN. Non-nitrogenous bisphosphonates indeed inhibit STAT3 (8). The other drug target, ATP6V1A, is connected to the IL1B pharmacogene by SUMO2 and FOS. FOS indeed has an established role in regulating the differentiation and activity of specific bone cell populations, both during normal development and in bone disease (9). Both FOS and JUN have reported association to IL1B in the context of fimbria-induced bone resorption (10). We were unable to find studies associating four inferred genes: JAK2, SUMO2, RRAS and PIK3CA with the tiludronate mechanism of action. However, Ras is associated with the action of Nitrogen-containing bisphosphonates (11).
Constructed pathways are closer to hits in drug-based genome-wide association studies (GWAS) of warfarin, paclitaxel and gemcitabine
We evaluated the pathways of three drugs: warfarin (12), paclitaxel (13) and gemcitabine (14) against drug-specific GWAS, selected based on the relatively large number of published gene hits (Supplementary Methods, section 1). Indeed, inferred genes in the warfarin-specific pathway had higher rank than other genes (Wilcoxon ranked sum test, p<0.02) or genes in the warfarinspecific randomly constructed pathways (p<0.01). The inferred genes also displayed warfarin specificity by obtaining lower p-values than inferred genes in 111 of the other 112 drug-specific pathways p=0.009). For paclitaxel, none of the 13 published GWAS hits overlapped the paclitaxel-specific pathway, but were closer to the paclitaxel-inferred genes than randomly selected genes (p=0) or inferred genes in the random pathways (p<0.01). Paclitaxel-specific pathway was also closer to paclitaxel hit genes of higher, yet significant, p-values (p=0, Supplementary Methods, section 1). Similarly, seven hits from a GWAS on gemcitabine were significantly closer to gemcitabine-inferred genes than random sets of genes or inferred genes in the random pathways (p=0 and p<0.02, respectively).
Association between yeast genes modulating response to doxorubicin and doxorubicinspecific pathway genes
Several yeast genes modulating the response to doxorubicin, reported in the Saccharomyces genome database (15), support our doxorubicin-specific pathway. Small ubiquitin-related modifier pathway is a major determinant of doxorubicin cytotoxicity in S. cerevisiae (16).
Indeed, our doxorubicin-specific pathway includes three members of the small ubiquitin-related modifier protein family (SUMO1, SUMO2 and SUMO4). In the doxorubicin pathway, SUMO4 connects to the breast cancer-associated gene BRCA1 (17) via the UBE2I. Indeed, S. cerevisiae mutants lacking the UBE2I yeast homolog (UBC9) are doxorubicin resistant (16). UBA2, also increasing resistance to doxorubicin (16), do not appear in our pathway but has direct physical interaction with pathway genes UBE2I, SUMO1 and SUMO2. Last, overexpression of SSL2 confers resistance to doxorubicin in yeast (18). The SSL2 human homolog ERCC3 do not appear in our pathway, but other members from the same gene family ERCC2 and ERCC6 do. It interacts with twenty pathway genes, including BRCA1.
Evaluation of cancer drug repositioning
We evaluated the repositioning of cancer drugs to other cancer types using PubChem bioassays (19). We downloaded all the bioassays associated with 34 cancer drugs appearing in our list, and filtered the studies testing any of 30 cancer types (Supplementary Methods, section 2). For each pair of a cancer drug and cancer types, we counted the number of studies listing the drug as active or inactive against that cancer type. Excluding known cancer drug indications and inconclusive pairs (cancer drugs found both active and inactive against a cancer type across different studies) resulted in 361 drug-cancer type pairs. Only repositioning predictions found by the second criteria (finding disease-associated genes in another drug pathway) were enriched in these 361 pairs (hypergeometric test, p<0.05. odds-ratio=1.57).
Inferred pathways suggest novel associations between side effects and genes
Using a literature-curated gold standard set of associations between genes and side effects from (20), we assigned side effects to drugs based on the occurrence of these genes on our drugspecific pathways, resulting in 1628 predictions (Table S2) . Testing these drug-side effect predictions, we found that 26% of our predictions corresponded to known drug-side effect associations from (21).
Our drug-specific pathways can also associate genes with potential side effects (SEs). For 764
SEs associated with the 113 drugs, we computed the enrichment of genes within their pathways, accounting for similar drugs and correcting for multiple hypotheses (Supplementary Methods, section 3 and Figure S2 ). We obtained a final list of 135 gene-SE associations, spanning 33 genes and 50 SEs (Table S3) .
We evaluated our gene-SE predictions by querying PubMed and PMC for associations between 28 SEs from our prediction set and the genes in our network (Supplementary Methods, section 3). Nineteen SEs were significantly co-mentioned with the predicted associated genes (FDR <0.05). Out of the remaining nine SEs, three were co-mentioned with the predicted genes more frequently than other genes on average (3-87 fold higher on average, but with no significant pvalue). The remaining six side effects (bruxism, decreased libido, gingivitis, tongue discoloration, manic reaction and paranoid reaction) had very infrequent co-mentions with any gene (Wilcoxon rank sum test between the mean co-mentioning for these six SEs and other SEs, p<0.005). Additionally, we found that four of our associations overlapped the prediction set of Our gene-SE predictions display relatively low overlap with associations collected by (Kuhn, 2013). However, some of our predictions associate a gene with a side effect that is clinically related to the side effect reported in literature. One such example is HTR2A; it is associated with tremor whereas we predict association with myoclonus, twitching or ataxia (22, 23). HTR2A is also associated with anxiety and bipolar disorder and we predict manic reaction (24) . Some of our predictions (e.g. HTR2A and twitching or ataxia) do not appear in the published predicted set of (20), but appear on their SIDER2 website (21). Interestingly, ten of the associations from the prediction set of (20) did not pass our strict cutoffs in the drug-specific pathways but were enriched in our random pathways, which include only the true drug targets (p<2e -23 ).
We highlight two examples. First, we associated FKBP5 with glaucoma, and indeed it may be responsible for increased responsiveness in steroid-induced ocular hypertensive individuals and in patients with glaucoma through alteration of glucocorticoid receptor sensitivity (25) . Second, we associate COMT with extrapyramidal symptoms (EPS), and there are published associations between COMT polymorphism and EPS susceptibility (26) .
Inferred pathways may suggest novel associations between genes and PD drug interactions
Our drug-specific pathways may be used for associating genes with PD drug interactions (Supplementary Methods, section 4). Focusing on severe DDIs (i.e. DDIs which the drugs.com website recommends as "generally avoid" or "contraindicate"), we verify that interacting drugs tend to share more genes than non-interacting drugs (Wilcoxon ranked sum test below FDR of 0.05).
We found fifteen genes enriched for co-occurrence in drug-specific pathways of severely interacting drugs (Supplementary Methods, section 4, Table S4 and Figure S3 ). In order to evaluate our gene-DDI predictions, we queried PubMed and PMC for the co-mentioning of the fifteen genes with all possible drug combinations. Ten of the genes had more frequent comentioning with severely interacting drug pairs than with non-interacting drug pairs (FDR of 0.05).
We highlight two examples: The mouse double minute 2 homolog (MDM2) gene appears in several interactions leading to cardiotoxicity (e.g. between trastuzumab and three of the anthracyclines family such as doxorubicin). Indeed, research conducted on rats suggests that the doxorubicin downregulates MDM2, further affecting the TGF-β/Smad p53 pathway leading to cardiotoxicity (27) . Other work suggests that the adverse cardiac events observed with trastuzumab may also stem from its negative regulation of MDM2 events which impairs the same p53 mechanism, resultantly promoting apoptosis leading to cardiac dysfunction (28) .
Second, we predicted JAK2 to be associated with increased risk of hematologic toxicity. These DDIs include known bone marrow suppressants such as azathioprine, peginterferon and daunorubicin (according to the NIH DailyMed drug labels, and see also (29, 30) ). In addition, interferon is indeed thought to activate Jak2 via IFGR1 and IFGR2 (31) and JAK2 mutation was associated with human myeloproliferative disorders (group of diseases of the bone marrow) (32).
Methods

Constructed pathways are closer to hits in drug-based genome-wide association studies (GWAS) of warfarin, paclitaxel and gemcitabine
In the warfarin dosage GWAS evaluation, we used the linear regression score of single nucleotide polymorphisms (SNPs) relative to warfarin dose (12). We mapped SNPs to genes using dbSNP based on build hg19 of the human genome, including SNPs within gene introns and exons as well as 10KB upstream (5') and 3KB downstream (3') of the gene as described in (33) .
We chose the highest scoring SNPs per gene in case a gene had more than one associated SNP.
We next performed a Wilcoxon ranked sum test between the scores of the warfarin-specific inferred genes to three sets of genes: (1) all other genes, (2) inferred genes in the warfarin random pathways, and (3) inferred genes in drug-specific pathways of other drugs.
For the paclitaxel GWAS evaluation, we retrieved the thirteen top hit genes from a study of the onset and severity of sensory peripheral neuropathy in response to paclitaxel (13). We compared the minimal network distance between the top GWAS hit genes to paclitaxel-specific pathway with the minimal distance between the top hit genes and paclitaxel random pathways. We also show that paclitaxel-specific pathway is closer to even larger sets of gene hits, computed using a p-value threshold ranging between e-6 and 0.001 (gene p-values taken from (13), personal communication). We performed the same type of network-distance comparison for gemcitabine
Evaluation of cancer drug repositioning
In order to map cancer drugs to PubChem (19) identifiers, we used DrugBank (34) mapping to PubChem and manual PubChem queries. For mapping bioassays to cancer types, we searched the bioassay description and comment fields for the disease name (e.g. "Breast cancer") or a related cell-line (e.g. MCF7), where cell-lines to cancer types mapping were obtained from the University of Michigan Cell Line Knowledge Base (35) .
Inferred pathways suggest novel associations between side effects and genes
In order to identify genes associated with side effects, we assume that if a gene is enriched in drug-specific pathways where the drugs are associated with a common side effect, then this gene might be part of the molecular mechanism of the side effect ( Figure S2) . A similar idea was applied by (20) for drug targets.
We downloaded drug-side effect (SE) associations from SIDER (21) database and focused on side-effects associated with more than five drugs and less than 56 drugs (half the number of drugs in our set), totaling in 765 SEs. Additionally, we excluded genes that appear in less than five drug-specific pathways. In order to avoid bias caused by similar drugs, we selected a nonredundant set of drugs for the enrichment analysis. We computed the similarity between two drugs based on the Jaccard score between the corresponding drug-associated genes, (drug targets, pharmacogenes and disease genes) and iteratively removed drugs with similarity score above 0.6 (corresponding to the same percentage of drugs with a Tanimoto coefficient of 0.7, which is limited to small molecules which have structure SMILES(36) representation (37)). Randomly selecting different drugs to remove from each similar drug pair, we created 100 different nonredundant sets. In each set, we computed gene enrichment in pathways of drugs associated with each of the 765 SEs, correcting for multiple hypotheses using FDR of 0.05. The final score of each gene-SE is the percentage of times it passed FDR correction across all non-redundant sets.
Our final list of gene-SE associations contained only gene-SE associations above a conservative score of 0.5.
For validating our gene-SE predictions against literature, we queried PubMed and PMC for all pairwise associations between SEs which had more than one predicted associated gene and each of the genes in our interaction network. We manually excluded the 62 ambiguous gene names.
Inferred pathways may suggest novel associations between genes and PD drug interactions
We performed the same procedure described in the gene-SE prediction to ensure non-redundancy between drugs.
We tested whether the propensity of two drugs to interact clinically is associated with the number of genes in common between their drug-specific pathways. Using a gold-standard set of PD drug interactions (DDIs) from (38), we verified that drug-specific pathways of severely interacting drugs tend to share more genes than drug-specific pathways of non-interacting drugs (Wilcoxon ranked sum test, all non-redundant sets below FDR of 0.05).
To associate genes with DDIs, we computed the enrichment (with FDR<0.05) of co-occurring genes between drug-specific pathways for known severely interacting pairs of drugs ( Figure S3 ).
As a conservative measure, we considered only genes enriched across all non-redundant drug sets. (7) Murakami, H., Takahashi, N., Tanaka, S., Nakamura, I., Udagawa, N., Nakajo, S. . Tiludronate-specific pathway. Red nodes are tiludronate drug targets, bluetiludronate pharmacogenes, yellow -genes associated with Paget's disease of the bone and light blue nodes are connector genes inferred by our method. Edge colors denote the combination of colors of the endpoints (orange leads from drug target to a disease gene, purple from a drug target to a pharmacogene and green from a pharmacogene to a disease gene). Gray interactions display the "highways" used to construct the pathway. Figure S2 . Illustration of the side effect-gene prediction scheme. We compute enrichment of genes occurring on drug-specific pathways within a set of drugs having the same side effect. Figure S3 . Illustration of the drug interaction-gene predictions. We compute enrichment of genes co-occurring in drug-specific pathways where the two drugs are interacting.
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